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promoting acetylation, dimerization and function in Treg cells.Wenowshow that theubiquitin-speciﬁc protease,
Usp7, controls Treg function largely by stabilizing the expression and promoting the multimerization of Tip60
and Foxp3. Genetic or pharmacologic targeting of Usp7 impairs Foxp3+ Treg suppressive functions, while
conventional T cell responses remain intact. As a result, pharmacologic inhibitors of Usp7 can limit tumor growth
in immunocompetent mice, and promote the efﬁcacy of antitumor vaccines and immune checkpoint therapy
with anti-PD1 monoclonal antibody in murine models. Hence, pharmacologic therapy with Usp7 inhibitors
may have an important role in future cancer immunotherapy.






Lung cancer is the leading cause of death from cancer among men
(28%) and women (26%), causing an estimated 158,040 deaths in the
US in 2015 (American_Cancer_Society, 2015). The 5-year survival rate
for all stages of lung cancer combined is currently only 17%, regardless
of progress in surgical management, radiation, chemotherapy and on-
going developments in immunotherapy (American_Cancer_Society,
2015). Hence, there is a major need for new insights into the pathogen-
esis and management of lung cancer.
Tumors have distinctive properties of growth, invasion andmetasta-
sis (Hanahan and Weinberg, 2000), and the ability to evade immune
destruction (Zitvogel et al., 2006). The latter is not because tumor cells
lack antigenicity (Curiel, 2007). Rather, while tumor-inﬁltrating CD8 T
cells are associated with improved clinical outcomes, accumulation of. Hancock).
n, Massachusetts, USA.
. This is an open access article underFoxp3+ T-regulatory (Treg) cells in tumors and/or draining lymph
nodes has a negative prognostic effect for many solid tumors, including
non-small cell lung cancer (O'Callaghan et al., 2015; Petersen et al.,
2006; Woo et al., 2001). There is great interest in targeting inhibitory
molecules expressed by immune cells, such as CTLA-4, PD1 and PD-L1
(Brahmer et al., 2012; Sharma et al., 2011; Topalian et al., 2012), and
although some monoclonal antibodies (mAbs) to so-called immune
checkpoints, e.g. anti-CTLA-4 mAb, probably bind Tregs and promote
antibody-dependent cytolysis, there are no Treg-speciﬁc Abs (Pardoll,
2012). In experimental tumor models, beneﬁcial strategies include de-
pletion of Foxp3+ Tregs using CD4 or CD25 mAb, cyclophosphamide,
IL-2-coupled toxin, or diphtheria-coupled toxin in so-called DEREG
mice; use of agents that affect Treg development such as COX-2/PGE2,
TGF-β, aromatase, STAT3 or p38 MAPK inhibitors, and TLR agonists;
and antibodies that affect Treg recruitment (CCR4) or function (CTLA-
4, PD-1, GITR, IL-10, TGF-β) (Beyer and Schultze, 2006; Curiel, 2007;
Dougan and Dranoff, 2009; Dyck et al., 2016; Gallimore and Godkin,
2008; Gallimore and Simon, 2008; Ha, 2009; Ke et al., 2008;
Nishikawa and Sakaguchi, 2010; Qin, 2009; Zitvogel et al., 2008).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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may reﬂect co-targeting of activated effector T cells (Antony et al., 2005;
Attia et al., 2005; Knutson et al., 2006). These various approaches also
bring increased risks of autoimmunity (Dranoff, 2005) or inﬂammatory
toxicity (Fietta et al., 2009), and have only transient effects (Powell et
al., 2007).
In studies of the post-translational modiﬁcations of Foxp3, we have
shown that modulation of Foxp3 protein acetylation by genetic or phar-
macologic targeting of the histone/protein acetyltransferases (HATs),
p300 and CBP, can dampen Treg suppressive function and promote
anti-tumor immunity (Liu et al., 2013). These ﬁndings indicate the
potential for pharmacologic regulation of Tregs without impairing
host immune responses or inducing autoimmunity. In ongoing studies
of additional members of the three main HAT families (GNAT, p300/
CBP and MYST) (Roth et al., 2001), only deletion of the MYST family
member, Tip60, led to lethal autoimmunity (Xiao et al., 2014). Indeed,
the severity of autoimmunity seen in mice with conditional Treg
deletion of Tip60 was comparable to that in Scurfy mice that have a
frame-shift mutation in the Foxp3 gene.
We now report that both Tip60 and Foxp3 proteins are subject
to ubiquitination and proteasomal degradation, whereas the actions
of a deubiquitinating (DUB) enzyme, ubiquitin-speciﬁc protease,
Usp7 (also known as HAUSP) (Cummins et al., 2004; Li et al., 2004),
counteract these events and promote Tip60 and Foxp3 stability and,
consequently, Treg suppressive function. Importantly, from a transla-
tional perspective, we further show that use of speciﬁc Usp7 inhibitors
can, in a dose-dependent manner, promote anti-tumor immunity by
dampening Treg activity while preserving key T effector cell functions,
providing a new approach to cancer immunotherapy.
2. Materials and Methods
2.1. Animals
We purchased standard CD90.2+ C57BL/6 (B6), B6/CD90.1+,
BALB/c, and B6/Rag1−/− mice (The Jackson Laboratory). CD4cre
mice (Lee et al., 2001), Foxp3YFP-cre mice (Rubtsov et al., 2008),
Foxp3eGFP-Cre-ERT2 mice (Rubtsov et al., 2010), Tip60ﬂ/ﬂ mice (Xiao et
al., 2014), and Usp7ﬂ/ﬂmice (Kon et al., 2011) were described previous-
ly. For tamoxifen induction of Foxp3eGFP-Cre-ERT2, 40 mg of tamoxifen
was dissolved in 100 μl ethanol, diluted by adding 900 μl of olive
oil, and mice were gavaged with 200 μl tamoxifen emulsion per treat-
ment. Mice were housed under pathogen-free conditions and used at
3–4 weeks of age, unless speciﬁed.
2.2. Antibodies and Plasmids
We purchased conjugated monoclonal antibodies (mAbs) for ﬂow
cytometry (BD Pharmingen), plus anti-Foxp3 mAb (FJK-16 s,
eBioscience), and rabbit antibodies to β-actin, Usp7, p53 and Mdm2
(Cell Signaling), and Tip60 (Cell Signaling and Millipore). Flow cytome-
try was performed on a Cyan ﬂow cytometer (Beckman Coulter), and
data analyzed with FlowJo 8 software (Tree-Star). CD4+YFP+(Foxp3+)
and CD4+YFP−(Foxp3−) cells were sorted from age- and sex-matched
Foxp3YFP-cre or Foxp3YFP-creUsp7ﬂ/ﬂ mice using a FACS Aria cell sorter
(BD Bioscience, UPenn Cell Sorting Facility). We purchased from
Addgene plasmids expressing FLAG-tagged Foxp3 (pFLAG-Foxp3),
pFLAG-Tip60, HA-tagged ubiquitin (pHA-Ub) and pUsp7, and 293 T
cells were transiently transfected, as described (Xiao et al., 2014).
2.3. Hematology and Autoantibody Detection
Citrated blood samples were tested using an automated hematology
analyzer modiﬁed and calibrated for mouse blood samples. Pooled sera
from male Usp7−/− or WT mice were diluted 1:5 and incubated with
cryosections from normal male and female C57BL/6 mice, washed inPBS, followed by goat anti-mouse IgG FITC-conjugated secondary anti-
bodies (Jackson ImmunoResearch Laboratories, 1:200). In addition to
pooled WT healthy sera, controls included incubation with secondary
antibody alone. Pooled sera from NZB mice with known autoantibodies
served as positive controls. If any autoantibodies were detected, serum
from each mouse was re-analyzed separately.2.4. Treg Suppression Assays
CD4 + CD25- T-effector (TE) and CD4 + CD25+ Treg cells were
isolated from Foxp3YFP-cre or Usp7−/−mice using CD4+ CD25+ Treg
isolation kits (130–091-041, Miltenyi Biotec). Cell Trace Violet-labeled
or CFSE-labeled Teff cells (5 × 105) were stimulated with CD3 mAb
(5 μg/ml) in the presence of 5 × 105 irradiated syngeneic T-cell depleted
splenocytes (130-049-101, Miltenyi Biotec) and varying ratios of Tregs
(Tao et al., 2007). After 72 h, proliferation of TE cells was determined
by analysis of Cell Trace Violet dilution or CFSE dilution.2.5. Treg Conversion from Conventional T Cells
CD4+YFP− TE cells isolated by cell sorting from Foxp3YFP-cre mice
were incubated with CD3/CD28 beads (Invitrogen), IL-2 (10 U mL−1)
and TGF–β (2 ng/ml) for 3 days and analyzed by ﬂow cytometry.2.6. Homeostatic Proliferation
CD90.1+CD4+CD25− TE cells (1 × 106) were mixed with 0.5 × 106
CD4+ YFP+ Tregs sorted from FOXP3YFP-cre or Usp7−/− mice
(CD90.2+), and adoptively transferred to Rag1−/− mice (Tao et al.,
2007). Spleen and lymph nodes were isolated at 7 days, and CD90.1+
CD4+ T-cells determined by ﬂow cytometry. In separate studies of
Treg survival, we undertook cell sorting and adoptively transferred
0.5 × 106 CD4 + YFP+ Usp7−/− or WT Tregs into syngeneic
Rag1−/−mice, and 4 weeks later, used ﬂow cytometry to determine
the numbers of each Treg population in peripheral lymph nodes and
spleens.2.7. Cardiac Transplantation
Intercrossed Usp7ﬂ/ﬂ and Foxp3eGFP-Cre-ERT2 C57BL/6 mice were
engrafted with fully MHC-disparate BALB/c cardiac allografts mice,
and Treg-dependent allograft survival induced by costimulation block-
ade with i.v. injection of CD154 mAb (250 μg) plus 5 × 106 donor
splenocytes (Tao et al., 2007). The effects of acute Usp7 deletion in
Foxp3+ Tregs of adult mice were assessed by treating recipients with
tamoxifen, or carrier, at transplantation (n = 6/group). The effects of
concomitant Usp7i therapy on costimulation blockade-induced cardiac
allograft survival (BALB/c- N C57BL/6) in WT recipients (n = 6/group)
was tested by daily injection of Usp7i (1mg/kg/day, 14 days), or carrier
alone, for 2 weeks from engraftment.2.8. Quantitative PCR (qPCR)
RNA from Foxp3+ Treg or Foxp3- TE cells, freshly isolated from
pooled lymph node and spleen samples, or isolated and activated with
CD3/28 mAb-coated beads (Invitrogen), was obtained using RNeasy
Kits (Qiagen). RNA was isolated from tumor samples using STAT-60
(Amsbio). cDNA was synthesized with TaqMan reverse transcription
reagents (Applied Biosystems). qPCR was performed using TaqMan
Universal PCR Master Mix (Applied Biosystems), and speciﬁc primers
from Applied Biosystems, and gene expression data were normalized
to 18S RNA.
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USP7i compounds, and assays of USP7 and total DUB activity were
described previously (Chauhan et al., 2012; Weinstock et al., 2012).
The UbiTest kit (LS catalog #UM411)was developed by LifeSensors. Im-
munoprecipitation andWestern blotting were performed as previously
described (Xiao et al., 2014).
2.10. ChIP Assays
DNA-chromatin complexes were prepared from 2 × 106 Tregs using
EZ-Magna CHIP A Chromatin Immunoprecipitation Kits (17-408,
Upstate), and genomic DNA immunoprecipitated using anti-Tip60 Ab
or control IgGwas probed by RT-PCR using primers for Foxp3 promoter:
forward 5′-TTCCCATTCACATGGCAGGCTTCA-3′ and reverse 5′-TGAG
ATAACAGGGCTCATGAGAAACC ACA-3′; Foxp3 CNS1 region: forward
5′-TAAAGGAGACTGGAAGCCAACATGG-3′ and reverse 5′-ATAGAAGA
CATACACCACGGCG-3′; Foxp3 CN2 region: forward 5′-CAGAAAAA
TCTGGCCAA GTT-3′ and reverse 5-‘AGGACCTGAATTGGATATGGT-3′;
and Foxp3 CNS3 region: forward 5′-AAT GAATGAGACACAGAACT
ATTAAGATGA-3′ and reverse 5′-CAGACGGTGCCACCATGAC-3′.
2.11. Microarrays
RNAwas extractedwith RNeasy kits (Qiagen) from Tregs isolated by
cell-sorting of YFP+ cells, and RNA integrity and quantity were
analyzed by photometry (DU640; Beckman-Coulter). Microarray
experiments were performed with whole-mouse-genome oligoarrays
(Mouse430a 2.0; Affymetrix), and array data analyzed with MAYDAY
2.12 (Battke et al., 2010). Array data were subjected to robust
multiarray average normalization. Normalized data were used for
calculating fold changes of genes that were increased or decreased in
expressionwith the Student's t-test, and datawith N1.5–fold differential
expression (p b 0.05 with Storey's FDR b 0.3) were included in the anal-
ysis. We assessed functional annotation clustering using the Database
for Annotation, Visualization and Integrated Discovery (DAVID)
(Huang da et al., 2009). Data underwent z-score transformation for dis-
play.Microarray datawere deposited inNCBI Gene ExpressionOmnibus
under accession code GSE72988.
2.12. Cell Lines and Tumor Models
TC1 cells were derived from mouse lung epithelial cells that
were immortalized with HPV-16 E6 and E7, and transformed with the
c-Ha-ras oncogene (Lin et al., 1996). The murine AE17.ova mesothelio-
ma cell line was derived from mesothelioma cells developing in mice
treated i.p. with asbestos, and then stably transduced with chicken
ovalbumin (Jackaman et al., 2003). For tumor studies, each mouse was
shaved on their right ﬂank and injected s.c. with 1.2 × 106 TC1 or 2 ×
106 AE17 tumor cells. For Usp7i experiments, mice received Usp7i or
DMSO via Alzet pumps inserted 7 days after initial tumor injection.
Tumor volume was determined by the formula: (3.14 × long
axis × short axis × short axis)/6.
In Ad.E7 vaccination studies, 1 × 106 TC1 (E7+) cells were injected
subcutaneously into the right ﬂanks of mice, and one week later, mice
bearing TC1 ﬂank tumors (~100mm3 in size)were either left untreated,
or vaccinated subcutaneously in the left ﬂank (contralateral to the
tumor) with 1 × 109 plaque forming units (pfu) of Ad.E7 vector, as
previously described (Haas et al., 2006). Three days following initial
vaccination, mice received a booster vaccine of 1 × 109 pfu of Ad.E7 in
the left ﬂank and were thereafter untreated or received pumps deliver-
ing Usp7i (1mg/kg/day). Tumor sizes weremonitored twice/week, and
antigen-speciﬁc T cells were identiﬁed using HPV-E7 tetramers, as
described (Haas et al., 2006).
In PD-1 studies, mice with established TC-1 ﬂank tumors were
given i.p. injections of saline (control), anti-mouse PD-1mAb (BioXcell)(5mg/kg/4 days), Usp7i (1mg/kg/day, Alzet pump), or the combination
of anti-PD1 mAb and Usp7i, and tumor sizes were monitored twice/
week. In tumor studies, staff were blinded as to the contents of the
Alzet pumps used in each experiment, and mice were followed until
the size of tumors in control mice reached the size limit, or met
additional limiting criteria, speciﬁed by our IACUC protocol.2.13. Statistics
Data were analyzed by GraphPad Prism 5.0d. All normally distribut-
ed data were displayed as mean ± standard deviation (SD). Measure-
ments between 2 groups were performed with a Student's t-test or
Mann-Whitney U test. Groups of 3 or more were analyzed by one-way
analysis of variance (ANOVA) or the Kruskal-Wallis test, with corre-
sponding post-hoc tests (Tukey for ANOVA and Dunn's multiple com-
parison test for Kruskal-Wallis test). Survival analysis was calculated
using Log rank (Mantel Cox) test.2.14. Study Approval
Studies were approved by the Institutional Animal Care and Use
Committee of the Children's Hospital of Philadelphia (IAC 13-000561
and 2014-1-1047).3. Results
3.1. Developmental Deletion of Usp7 in Tregs Induces Lethal Systemic
Autoimmunity
Our interest in Usp7 developed in several ways. First, recently
published ChIP studies indicated that multiple Usp genes were targets
of FOXP3 in human Tregs (Sadlon et al., 2010), suggesting a possible
mechanism to control gene expression in Treg cells. Second, analysis
of published databases showed that of various Usp genes, expression
of Usp7 in particular was markedly decreased by Foxp3 ablation in mu-
rine Tregs (Fig. S1A). Third, both Foxp3+ Tregs and Foxp3- T-effector
(Teff) cells, isolated from pooled lymph nodes and spleens, expressed
Usp7 protein (Fig. S1B). Fourth, using immunoprecipitation studies,
we found that Foxp3 and Usp7 proteins could co-associate (Fig. S1C).
Fifth, a Dutch group reported that Usp7 regulated expression of Foxp3
in murine Tregs by promoting its deubiquitination and preventing its
proteasomal degradation (van Loosdregt et al., 2013). Since none
of these studies involved genetic deletion or the application of Usp7-
speciﬁc pharmacologic inhibitors (Usp7i), we developed the current
project to explore the signiﬁcance of ubiquitination as a post-transla-
tional modiﬁcation of potential signiﬁcance as a therapeutic target in
Foxp3+ Treg cells.
We conditionally deleted Usp7 in murine Tregs by crossing Usp7ﬂ/ﬂ
and Foxp3YFP/Cre mice (Fig. 1A). The resultant conditionally deleted
(and hereafter termed Usp7−/−) mice were born at expected
Mendelian ratios, but pups failed to thrive, showed progressive wasting
by 3 weeks, and died by 4 weeks of life (Fig. 1B). The development of
autoimmunity in these Usp7−/−mice was evidenced by: (i) thymic at-
rophy, lymphadenopathy and splenomegaly (Fig. 1C); (ii) pancytopenia
with decreased hemoglobin and hematocrit levels (Fig. 1D); and (iii)
extensive mononuclear cell inﬁltrates in lung, liver, pancreas and
other tissues that were not present in age- and gender-matched
controls (Fig. 1E, Table S1). In addition, in contrast to age- and gender-
matched controls, 80% of Usp7−/− mice developed autoantibodies
directed against gastric parietal cells, and 40% developed autoantibodies
against pancreatic islet cells, endomysium, smooth muscle, keratin, and
renal proximal tubular cell brush borders (Fig. 1F, Table S2). Hence, con-
ditional deletion of Usp7within developing Foxp3+ Tregs led to severe
autoimmunity and death of affected mice within 4 weeks of birth.
Fig. 1. Characterization of mice with conditional deletion of Usp7 in their Foxp3+ Treg cells. Unless indicated, data are frommale mice aged 3–4 weeks and are representative of 4 mice/
group. (A) Western blots showing deletion of Usp7 protein in Usp7−/− Foxp3+ Treg but not conventional T (Tcon) cells, following cell-sorting of YFP+ and YFP- cells from USP7ﬂ/
ﬂFoxp3cre mice and Foxp3cre controls. (B) Kaplan-Meier plot of the survival of Usp7−/− vs. WT mice (p b 0.01, 6 mice/group). (C) Thymus, spleen and lymph nodes from Usp7−/−
versus WT mice. (D) Hematologic parameters (mean ± SD) in Usp7−/− versus WT mice, including white blood cell (WBC), platelet (PLT) and red blood cell (RBC) counts, plus
hemoglobin (HGB), hematocrit (HCT) and mean corpuscular volumes (MCV), using blood samples from 6 mice/group; *p b 0.05, and **p b 0.01. (E) Representative histologic ﬁndings
of dense mononuclear cell inﬁltrates in the lungs of Usp7−/− mice, periportal inﬁltration of the liver, and peri-islet inﬁltration of the pancreas; sections from age- and sex-matched
littermate controls are shown as insets; scale-bars indicate 100 μ. (F) Sera of Usp7−/− but not WT mice contained autoantibodies directed against gastric parietal cells of stomach,
islet cells of pancreas, endomysium, smooth muscle cell membranes, keratin, and brush borders of renal proximal tubular cells; scale-bars indicate 100 μ.
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103L. Wang et al. / EBioMedicine 13 (2016) 99–1123.2. Effects of Usp7 Deletion on Foxp3+ Treg Development and Function
Conditional deletion of Usp7 in Tregs did not markedly affect thymic
CD4 or CD8 T cell development, but was associated with considerably
increased T cell numbers and activation in lymph nodes and spleen
(Fig. 2A, Fig. S2, p b 0.01), including increased CD69+ activated T cells
and increased CD62LlowCD44high effector/memory cells in both CD4
and CD8 T cell lineages (Fig. 2A, Fig. S2, p b 0.01). Deletion of Usp7 did
not appear to affect CD4 + Foxp3+ Treg development in the thymus,
as the numbers of CD4 + YFP+ or CD4+ Foxp3+ Tregs were compa-
rable to those of littermate controls (Fig. 2B, Fig. S3). However,
Usp7−/− Tregs displayed some very unusual properties. First, though
the mean ﬂuorescent intensity (MFI) of Foxp3 staining in Tregs from
control vs. Usp7−/− targetedmicewas comparable (Fig. S3), the num-
bers of Treg cells in peripheral lymphoid tissues were signiﬁcantly re-
duced (Fig. 2B, Fig. S3, p b 0.01), and Usp7−/− Tregs were more
actively proliferating, even under basal conditions, than WT controls
(Fig. S4, p b 0.05). Second, qPCR analysis showed that Tregs lacking
Usp7 actually had increased levels of Foxp3 compared to WT controls
(p b 0.05), including following CD3/CD28 mAb-induced cell activation
(p b 0.05) (Fig. S5A). Third, despite their increased Foxp3 transcription,
Usp7−/− Tregs, in contrast toWT Tregs, produced the cytokines IL-2 and
IFN-γ at baseline (p b 0.01), and their production of both cytokines was
increased several hundred-fold upon cell activation (p b 0.01)
(Fig. S5B). These data indicate that while Foxp3+ Tregs are produced
in normal numbers in the thymus despite Usp7 deletion, and have
increased Foxp3 transcription and apparently normal levels of Foxp3 pro-
tein, these cells are quite abnormal. In particular, they fail to suppress IL-2
production, which is a signature function of Foxp3 protein in normal Treg
cells (Fontenot et al., 2005; Gavin et al., 2007), and they have reduced
survival in the periphery despite increased proliferative rates.
We also analyzed the effects ofUsp7deletion on the in vitro develop-
ment of inducible Tregs (iTregs) using Usp7−/− conventional T cells,
obtained bymating CD4cre and Usp7ﬂ/ﬂmice. These cells were activated
and cultured for 3 days in the presence of TGF-β and IL-2. Compared to
the iTreg conversion of WT T cells, iTreg development by cells lacking
Usp7 was reduced by N50% (p b 0.01) (Fig. 2C, Fig. S3). These ﬁndings
suggest a markedly reduced capacity for extra-thymic Treg develop-
ment as a result of peripheral conversion.
Microarray studies showed that Usp7 deletion in Tregs affected the
expression of several hundred genes (Fig. 2D), with decreased expres-
sion of many transcription factors important to Treg development and
stability (Fig. S6), including the Foxp3 co-regulators Eos and Gata1
(Fu et al., 2012; Rudra et al., 2012; Yang et al., 2016). Usp7 deletion
also increased Treg expression of genes associated with cell cycle, DNA
damage response, apoptosis and glycolysis pathways (Fig. 2D, Fig. S7).
The extensive changes in metabolic and pro-apoptotic gene expression
in Usp7−/− Tregs are consistent with their signiﬁcantly decreased
numbers in the periphery despite their concomitant increased
proliferation.
As anticipated by the development of aggressive autoimmunity in
Usp7−/− mice, the suppressive function of Usp7−/− Treg cells in vitro
was markedly impaired (Fig. 2E). The rapid onset of autoimmunity
and death in mice with conditional deletion of Usp7 during normal de-
velopment precluded in vivo studies of Treg function. Hence, to assess
the importance of Usp7 in the Foxp3+ Treg cells of adult animals, we
intercrossed Usp7ﬂ/ﬂ and Foxp3-eGFP/Cre-ERT2 C57BL/6 mice. Their proge-
ny developed normally and, as adults, displayed the anticipated normal
Treg-dependent acceptance of BALB/c cardiac transplants when treated
with CD154 mAb plus donor splenocyte transfusion (DST) (Hancock et
al., 1998; Lee et al., 2005). However, this potent therapy for induction of
Treg-dependent allograft tolerance was ineffective if corresponding
allograft recipients were treated with tamoxifen, from the day of
transplant, to deplete Usp7 in their Tregs (Fig. S8), and acute rejection
promptly ensued (Fig. 2F). Hence, Usp7 deletion during thymic
development, as well in adulthood when immune functions have fullydeveloped, leads to profound effects on mature Foxp3+ Treg cells and
disrupts their suppressive functions in vitro and in vivo.
3.3. Pharmacologic Inhibition of Usp7
To assess whether pharmacologic blockade of Usp7 could modulate
normal Foxp3+ Treg cell function, we evaluated several highly selec-
tive small molecule inhibitors of Usp7 (Usp7i), including the parent
compound P5091, and its derivative P0217564 (hereafter 564)
(Chauhan et al., 2012; Weinstock et al., 2012), whose potencies and
speciﬁcities are summarized in Table S3. We assayed the ability of
each compound to target the active site of Usp7 and thereby prevent
its interaction with an active site-directed probe, ubiquitin vinyl-meth-
yl-ester (Ub-VME) (Boudreaux et al., 2010). In studies using full length
Usp7, or just its catalytic domain, the pre-incubation of compound 564
prevented interaction of Usp7 and Ub-VME (data not shown). In studies
in which Jurkat cells were incubated with 564 (10 μM) for 2 h and then
washed free of compound, the Usp7i blocked N80% of Usp7 enzymatic
activity, and in pulse chase studies maintained ~50% inhibition at
48 h, but did not affect global deubiquitinase activity (Fig. 3A). In the
case of Foxp3+ Treg cells, the parent compound, P5091, and its deriva-
tives, including 564 (all at 10 μM), had potent and long-lasting inhibito-
ry effects onmurine Treg function in vitro; 2 h of pre-treatment of Tregs,
followed by their washing and use in 3-day suppression assays almost
completely abrogated Treg function (Fig. 3B). These sustained inhibitory
effects on Treg functionwere remarkable given the brief pre-incubation
and are indicative of essentially irreversible Usp7 inhibition.
Reduced Treg function as a result of Usp7i treatment was consistent
with the effects of gene targeting (Fig. 2), but the pharmacologic studies
also suggested amore complexmechanism of action than initially antic-
ipated. Thus, we detected a greater impact of Usp7i on a key HAT in
Tregs, Tip60, which critically regulates Foxp3 dimerization and Treg
function (Xiao et al., 2014), than on Foxp3 itself. First, cell-sorted Foxp3-
YFP+ Tregs isolated fromWTorUsp7−/−mice had comparable levels of
Foxp3 butmarkedly decreased Tip60 (Fig. 3C). Second, addition of com-
pound 564, for 5 h, to 293T cells transfected with Foxp3 had negligible
effects on expression of Foxp3 or endogenous Usp7, but downregulated
expression of endogenous Tip60 (Fig. S9). Third, Western blots of
Foxp3+ Treg cells activated for 2 h in vitro in the presence of 564
showed only negligible down-regulation of Foxp3 but a marked
decrease in Tip60 expression (Fig. 3C). These data suggested that Usp7
might be especially important to the regulation of Tip60 expression in
Treg cells.
To explore this further, we assessed the levels of Foxp3 expression in
Tip60−/− vs.WT Tregs. Tip60−/− Tregs are present in only exceeding-
ly low numbers following the conditional deletion of Tip60 in Foxp3+
Tregs (Xiao et al., 2014), precluding obtaining a sufﬁcient number of
cells for Western blotting. However, ﬂow cytometric staining, using
Tregs pooled from several such mice, showed markedly decreased
Foxp3 protein in Tip60−/− vs. WT Tregs, and qPCR analysis showed
their lower expression of Foxp3 and Ctla4 mRNA (p b 0.01), but in-
creased expression of IL-6 and IL-17 mRNA (p b 0.01), compared to
WT Treg cells (Fig. 3D). Corresponding conventional T cells from these
mice showed upregulated of Ctla4, IL-6 and IL-17 (p b 0.01), consistent
with their activation in the presence of reduced Treg numbers. Lastly,
ChIP studies showed that Tregs from conditionally deleted Usp7−/−
mice had decreased recruitment of Tip60 to the conserved noncoding
sequence-2 (CNS2) intron of the Foxp3 locus (Fig. 3E, pb0.01); this re-
gion is demethylated in mature Tregs and has a key role in maintaining
Foxp3 expression and Treg lineage stability (Zheng et al., 2010). Consis-
tent with data from conditionally targeted mice (Fig. 3C and Fig. S5), in
ChIP studies of WT Foxp3+ Treg cells (Fig. S10), Usp7i treatment de-
creased recruitment of DNA polymerase II (Pol II) to the Tip60 promoter
(p b 0.01), and decreased Foxp3 binding to the IL-2 promoter (p b 0.01).
These data point to the importance of Tip60 to maintaining optimal
Foxp3 expression in Treg cells.
Fig. 2. Effects ofUsp7 deletion on Foxp3+ Treg development and function. Data are from 3 to 4week oldmalemice, and are representative of results in 4mice/group; additional summary
graphs and statistical analyses are shown in Figs. S2–S7. (A) Generally normal proportions but increased activation of CD4 and CD8 cells (CD69+ CD44+ and CD62LlowCD44high cells) in
Usp7−/− versusWTmice. (B) Normal thymic Treg development but moderate decreases in YFP+ and Foxp3+ cells in peripheral lymphoid tissues of conditional Usp7−/− versusWT
mice. (C) Marked impairment of iTreg development in a 3-day in vitro assay involving culture of WT vs. CD4creUsp7ﬂﬂ T cells under activating conditions and in the presence of IL-2 plus
TGF-β. (D) Microarray analysis: Left panel shows a scatterplot of log2 transformed expression matrix data (means from 3/group) from YFP-sorted Foxp3cre Tregs with or without
conditional Usp7 deletion. Differential expression was determined by Student t-test p b 0.05 with N1.5-fold difference (log2 0.58), with red and blue representing genes up- and
downregulated by Usp7 deletion, respectively. Data underwent z-transformation for display. Right panel shows enrichment scores of the up- or downregulated genes calculated using
DAVID Functional Annotation Clustering. CC (cellular component), BP (biological process) and MF (molecular function) indicate gene ontology categories. (E) Usp7−/− vs. WT Tregs
in a standard Treg suppression assay. (F) The long-term cardiac allograft acceptance in FOXP3cre-ERT2Usp7ﬂﬂ recipients promoted by CD154 mAb/DST therapy was abrogated by
tamoxifen-induced depletion of Usp7 in recipient Foxp3+ Treg cells (p b 0.01, n = 5/group).
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Fig. 3. In vitro effects of Usp7i compounds. (A) Jurkat cellswere pulsed for 2 hwith compound 564 (10 μM),washed free of compound and cultured for theperiods indicated. Levels ofUsp7
were serially monitored by Western blotting (left panel), in conjunction with assays of Usp7 (middle panel) or global DUB activity (right panel), expressed as a percentage of activity of
corresponding DMSO-treated cells (mean± SD); *p b 0.05 and p b 0.01 vs. DMSO-treated cells. (B)Murine Treg cells were pre-incubatedwith DMSO or Usp7i compounds for 2 h, washed
and cultured for 3 days, at the ratios of Treg to CFSE-labeled Teff cells shown (mean± SE of triplicate wells, *p b 0.05 and **p b 0.01 vs. DMSO-treated cells at the corresponding ratio); a
representative result in which Tregs were pre-treated with compound 564 for 2 h is shown at right (inset ﬁgure indicates the proportion of proliferating cells in each well). (C)Western
blot analysis of, in the left panel, lysates of cell-sorted Foxp3YFP+ Tregs fromWT or Usp7−/−mice, and right, levels of endogenous Foxp3, Tip60 and Usp7 in Foxp3+ Treg cells cultured
under activating conditions for 2 h with or without the addition of compound 564, as shown. (D) Left panel shows mean ﬂuorescent intensity (MFI) levels of Foxp3 inWT or conditional
Tip60−/− Treg cells isolated from corresponding LN and spleen samples (representative of 4mice/group). Right panels show qPCR data (mean± SD, 4/group, **p b 0.01) of Foxp3, Ctla4,
IL-6 and IL-17mRNA levels using Teff and Treg cells isolated fromWT or conditional Tip60−/−mice. (E) ChIP studies assessing the levels of Tip60 at the Foxp3 promoter and CNS1, CNS2
and CNS3 sites in WT and conditionally deleted Usp7−/− Tregs (mean ± SD, 4/group, **p b 0.01). (F) Murine WT Tregs were incubated with DMSO alone, 564 (10 μM), or 564 plus
proteasome inhibitor (Bortezomib, BTZ) for 2 h, washed, lysed, subjected to TUBE pull-downs, and ubiquitinated substrates eluted and treated with Usp2 to separate ubiquitin from
substrate; proteins were then analyzed byWestern blotting. Data are expressed at right as fold change compared to using DMSO alone, and are representative of 3 separate experiments.
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106 L. Wang et al. / EBioMedicine 13 (2016) 99–112We next tested whether Usp7 regulated the ubiquitination and
proteasomal degradation of Tip60 and Foxp3, beginning with 293T
cells transfected with Foxp3, Tip60 and Usp7 (Fig. S11). Both proteins
were readily ubiquitinated, and ubiquitination was markedly sup-
pressed by co-transfection of Usp7, whereas Usp7i treatment promoted
Foxp3 and Tip60 ubiquitination (Fig. S11). In native gels, Foxp3 was
mainly expressed as dimers in 293T cells transfected with Foxp3
alone, whereas addition of tagged Usp7 resulted in expression of
Foxp3 monomers, as well markedly increased dimer and oligomer for-
mation (Fig. S12, left panel). Treatment with Usp7i decreased Foxp3
monomers, dimers and oligomers in transfected 293T cells (Fig. S12,
right panel). To assess whether Usp7i treatment also promoted
ubiquitination of Foxp3 in WT Treg cells, we studied Tregs cultured in
the presence of 564 and a proteasome inhibitor (MG132). Usp7i treat-
ment increased the levels of ubiquitinated Foxp3 in Tregs, and detection
was markedly enhanced by inclusion of MG132 to prevent the very
rapid proteasomal degradation of ubiquitinated Foxp3 (Fig. S13). Anal-
ysis using native gels showed that Usp7i treatment largely abrogated
detection of native Foxp3 monomers and dimers (Fig. S14, left), where-
as oligomers and high MW complexes of heavily ubiquitinated Foxp3
were detected in the presence of increasing concentrations of MG132
(Fig. S14, right). These data implicate proteasomal turnover of Foxp3
and Tip60 rather than their ubiquitin-dependent lysosomal degradation
(Du et al., 2013). Hence, Usp7 can promote assembly of higher order
complexes of Foxp3, including formation of Foxp3 dimers that are es-
sential for optimal Foxp3 binding to DNA in Treg cells, whereas Usp7i
treatment can disrupt assembly of such complexes. These actions likely
reﬂect the effects of Usp7 targeting on Tip60 expression, since Tip60, as
shown, is subject to Usp7-regulated deubiquitination, and normally
functions to promote Foxp3 acetylation and dimerization (Xiao et al.,
2014).
To further assess test the relative effects of Usp7i compound on
ubiquitination of Treg-associated Foxp3 and Tip60, we used a UbiTest
assay in which ubiquitinated proteins are pulled down using agarose
coupled to Tandem Ubiquitin Binding Entities (TUBE), followed by
their elution and treatment with a broadly acting DUB enzyme, Usp2,
to remove ubiquitin from substrate proteins. Using this DUB-assisted
ubiquitination detection assay, we found that whereas Tregs incubated
with 564 for 2 h in vitro showed only a modest increase in levels of
ubiquitinated Foxp3, the levels of ubiquitinated Tip60 were increased
by about 3-fold (Fig. 3F). Collectively, these data indicate that pharma-
cologic inhibition of Usp7 can markedly curtail Treg function, likely
through mechanisms that involve Tip60 rather than simply via direct
actions on Foxp3 alone.3.4. In Vivo Effects of Usp7 Targeting on Foxp3+ Tregs
To assess the in vivo effects of Usp7i, we ﬁrst injected mice daily for
5 dayswith Usp7i and isolated their Treg and Teff cells forWestern blot-
ting. The administration of Usp7i in vivo led to modestly decreased
Foxp3 protein and increased Ub-Foxp3 in Tregs (Fig. 4A). However,
Usp7i treatment resulted in markedly impaired Treg suppressive func-
tion (p b 0.01), and also increased the resistance of Usp7i-treated Teff
cells to suppression by untreated WT Tregs (p b 0.05) (Fig. 4B,
Fig. S15). To assess the direct effects of brief exposure of T cells to
Usp7i in vivo, we injected normal mice with compound 564 or diluted
DMSO carrier, and 2 h later, Treg and Teff cells were isolated for
biochemical studies. Brief Usp7i exposure had modest effects on the
levels of Foxp3 protein in Tregs, but markedly decreased concomitant
Tip60 protein expression, whereas levels of Tip60 in Teff cells were
less affected (Fig. 4C). In addition, extracts of the harvested cells were
treated with HA-Ub-VME that binds to the active site of Usp7, and
analyzed using SDS-PAGE. The in vivo binding of compound 564 to
the active site of Usp7 blocked the interaction of Usp7 with VME
substrate, revealing broadly equivalent interactions of compound 564and Usp7 enzyme in both Treg and Teff cells (Fig. 4D), whereas global
DUB activity in either cell population was unaffected (Fig. S16).
We next tested the effects of Usp7 targeting using 3 in vivo models.
The ﬁrst model assessed the effects of Usp7 deletion on Treg survival by
undertaking the adoptive transfer of conditionally deleted Usp7−/− or
WT Tregs into syngeneic immunodeﬁcient (C57BL/6 Rag1−/−) mice.
The numbers of Usp7−/− Tregs recovered from lymphoid tissues
after 4 weeks were markedly decreased compared to the numbers of
correspondingly transferred WT Tregs, suggesting that Usp7 deletion
impaired Treg survival in vivo (Fig. 4E), consistent with the reduced
numbers of Tregs found in Usp7−/−mice (Fig. 2B and Fig. S3). Prefer-
ential effects of Usp7i on Treg vs. Teff functionwere conﬁrmed in 2 sub-
sequent models. Next, in a 7-day model of homeostatic proliferation in
immunodeﬁcient mice, the treatment of Tregs with a Usp7i compound
prior to their adoptive transfer markedly impaired their ability to
suppress proliferation of co-transferred Teff cells, as compared to
Tregs exposed to carrier alone (Fig. 4F). Third, treatment with Usp7i
therapy for 2 weeks from the day of cardiac engraftment blocked the
Treg-dependent permanent allograft survival (BALB/c- N C57BL/6)
achieved in recipients treated with CD154 mAb plus donor splenocyte
transfusion (DST) (Fig. 4G). These studies point to the potential for
Usp7 targeting with selective small molecule inhibitors to impair Treg
functions, likely through effects on Tip60 and/or Foxp3, while preserv-
ing important protective host T cell responses.
3.5. Effects of Usp7i on Tumor Growth in Syngeneic Mice
Turning to several tumor models, we ﬁrst tested the ability of Usp7i
compounds to differentially impair Treg vs. Teff cell functions in cancer,
using syngeneic C57BL/6 mice bearing human papilloma virus (HPV)-
E7+ TC1 lung adenocarcinoma cells, as growth of TC1 cells in these
mice is Foxp3+ Treg-dependent (Liu et al., 2013). Therapy with
Usp7i, 564, at 1.0 or 6.0 mg/kg/day signiﬁcantly decreased the growth
of TC1 tumors in WTmice (Fig. 5A), but had no effect on tumor growth
when tested at the same dosing in immunodeﬁcient mice (Fig. 5B).
For mechanistic studies, additional groups were treated in the same
manner and tumor samples were collected at 6 days after onset of
USP7i therapy, when both 1.0 and 6.0 mg/kg/day of compound 564
had inhibitory effects on tumor growth (Fig. S17). At this point, the
higher dose (6 mg/kg/day) decreased intratumoral accumulation of
FOXP3+ Treg cells (p b 0.01, Fig. 5C), and both Usp7i concentrations
(1 and 6 mg/kg/day) increased tumor inﬁltration by CD8 T cells
(p b 0.05, Fig. 5D), including tumor-speciﬁc tetramer-positive CD8 T
cells recognizing HPV-E7 (p b 0.05, Fig. 5E), and IFN-γ-producing CD8
T cells (p b 0.01 Fig. 5F); representative ﬂow plots are shown in Fig. S18.
Usp7i compounds were next tested using AE.17 tumor cells, a sec-
ond model in which tumor growth is Foxp3+ Treg-dependent (Liu et
al., 2013). As with TC1 tumors, growth of AE.17 mesothelioma cells
was impaired by Usp7i administration in syngeneic WT C57BL/6 mice
(Fig. 6A), but Usp7i had no effect on tumor growth when tested in
syngeneic immunodeﬁcientmice (Fig. S19A). The lack of any signiﬁcant
direct effect of Usp7i on growth of TC1 or AE.17 cells in immunodeﬁ-
cient mice may reﬂect their lower levels of Usp7 than in the multiple
myeloma (MM1.S) cells used in a prior publication showing inhibitory
effects of Usp7i on tumor growth (Chauhan et al., 2012), as well as
their low levels of p53 and Mdm2 that are classic targets of Usp7
(Fig. S19B). Together with the TC1 data, these ﬁndings show that the in-
hibitory effects of Usp7i on tumor growth result from immune actions,
in particular, the differential effects of the Usp7i compounds on Treg
vs. Teff cells in these models.
To assess the effects of Usp7i administration in combination with
other anti-tumor therapies, we began by testing whether Usp7i use
could potentiate tumor vaccine therapy. TC1 tumor cells, which express
E7 derived from HPV, were implanted into WT B6 mice and on day 6
post-injection, mice were immunized with an adenovirus expressing
HPV-E6 and -E7 proteins and also received Alzet pumps delivering
Fig. 4. In vivo effects ofUsp7i compounds. For panels (A, B),micewere injectedwithUsp7i (10mg/kg/day, i.p.) for 5 days orDMSOalone (5mice/group). (A) Treg cells isolated fromUsp7i-
treated mice showed modestly decreased Foxp3 protein but increased Ub-Foxp3 compared to use of DMSO alone. (B) Treg cells isolated from Usp7i-treated mice showed markedly
impaired Treg suppressive function compared to DMSO-treated Treg controls (upper 2 rows). Usp7i therapy also impaired Teff cell responses to Treg suppression, as shown using Teff
cells from Usp7i or DMSO-treated mice and fresh, untreated Treg cells (lower 2 rows). Summary graphs and statistical analyses are shown in Fig. S15. (C) Western blots showing how
a bolus injection of Usp7i 24 h beforehand decreased Tip60 protein to a greater extent than Foxp3 protein in murine Treg cells (panel shows ratios of data for 564 vs. DMS0). (D)
Western blot analysis of the same cells as used in the previous panel, indicating that Usp7i compound bound to both Treg and Teff cells and decreased the interaction of Usp7 with
HA-Ub-VME substrate (signal ratios shown below). (E) The effect of conditional Usp7 deletion on the survival of Tregs in vivo was assessed by the adoptive transfer of Thy1.1+ Teff
(5 × 105) plus WT Treg or Usp7−/− Treg (1 × 105) cells into immunodeﬁcient (Rag1−/−) hosts, and harvesting LN and spleen samples at 1 month post-transfer for ﬂow cytometric
quantitation (n = 4/group, **p b 0.01). (F) The effects of Usp7i on Treg cell inhibition of the homeostatic proliferation on Teff cells in vivo was assessed by pre-incubation of murine
Tregs (5 × 105) with Usp7i (5 μM) or DMSO alone for 2 h, followed by their injection into Rag−/− mice, along with 1 × 106 Teff cells, and harvest of LN and spleen samples 7 days
later (n = 4/group, *p b 0.5, **p b 0.01). (G) Use of CD154 mAb plus DST induces permanent cardiac allograft survival in DMSO-treated hosts (BALB/c- N C57BL/6) whereas daily
injection of Usp7i (1 mg/kg/day, 14 days) from the time of engraftment restored acute allograft rejection (p b 0.01, n = 6/group).
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icantly more effective than either agent alone in limiting TC1 tumor
growth (Fig. 6B). Combination therapy signiﬁcantly increased the num-
bers of tumor-speciﬁc CD8+ tumor inﬁltrating lymphocytes (Fig. 6C,
with representative ﬂow plots shown in Fig. S20) and their production
of IFN-γ (Fig. 6D), while decreasing accumulation of intratumoral
Foxp3+ Treg cells (Fig. 6E). Usp7i therapy also added signiﬁcant
therapeutic activity when used in combination with anti-PD-1 mAb
therapy in mice bearing TC1 lung tumors (Fig. 6F). Collectively, these
studies show that Usp7i therapy has signiﬁcant beneﬁts when used asmonotherapy in tumor models in syngeneic hosts, as well as when
employed in combination with other forms of immunotherapy to
promote antitumor immunity.
4. Discussion
Studies of HDAC and HAT enzymes in Foxp3+ Treg cells show that
their regulation of the acetylation of lysine residues within Foxp3
protein is important to the development and maintenance of Treg
cells (Li et al., 2007; Liu et al., 2014; Liu et al., 2012; Tao et al., 2007;
Fig. 5. Effects of Usp7imonotherapy on host anti-tumor immune responses. TC1 lung adenocarcinoma cells (1.2 × 106)were injected s.c., and once tumor volumes had reached ~150mm3,
mice (8–10mice/group)were randomized and received either no therapy, or Usp7i (compound 564) at 0.6, 1.0 or 6mg/kg/day, via 14-day Alzet pumps. (A) Inhibitory effects of Usp7i on
tumor growth in syngeneic immunocompetent C57BL/6mice; left panel shows serial tumor volumes (mean±SD), and right panel shows individual tumorplots at day 16of Usp7i therapy
(**p b 0.01). (B) Lack of effects of Usp7i on tumor growth in immunodeﬁcient Rag1−/− C57BL/6 mice; left panel shows serial tumor volumes (mean ± SD), and right panel shows
individual tumor plots at day 14 of Usp7i therapy. Panels (C–F) were obtained from tumors in additional mice that were harvested at day 6 of Usp7i therapy (see Fig. S11), and show
data from 4 mice/group (mean ± SD), *p b 0.05, p b 0.01). (C) Inhibitory effects of Usp7i on numbers of intratumoral YFP+ Foxp3+ Treg cells. (D) Usp7i administration impaired CD4
T cell accumulation but promoted intratumoral CD8 T cell recruitment. (E) Usp7i therapy increased tumor-speciﬁc tetramer-positive CD8 T cells. (F) Usp7i therapy increased
intratumoral production of IFN-γ by CD8 T cells.
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ing the acetylation-dependent dimerization of Foxp3 (Song et al., 2012;
Xiao et al., 2014). This is an irreplaceable function of Tip60, since its con-
ditional deletion in Tregs, but not that of any other individual HAT, leads
to rapid and lethal autoimmunity (Xiao et al., 2014). In the absence of
their acetylation, multiple lysines of Foxp3 can be ubiquitinated and
lead to proteasomal degradation of Foxp3 protein (van Loosdregt et
al., 2010). We previously noted that both Foxp3 and Tip60 in Tregswere subject to proteasomal degradation (Xiao et al., 2014), but did
not dissect the regulatory mechanisms. The current study now shows
a major role for a single DUB, Usp7, in determining the fate of Foxp3
and Tip60 in Treg cells, thereby providing a target for therapeutic mod-
ulation of Treg function in the context of anti-tumor therapy.
Given the importance of Foxp3 and TIP60 in Treg biology, it is not
surprising that regulatory mechanisms exist to limit their proteasomal
turnover. In mammals, ~100 DUBs that hydrolyze the isopeptide bond
Fig. 6. Additional effects and combination therapies involving USP7i administration. (A) Effects of Usp7i therapy on the growth of AE.17 tumor cells in vivo. Usp7i therapy (6 mg/kg/day)
decreased the growth of AE.17 tumor cells in syngeneicWT C57BL/6 mice (**p b 0.01); mean ± SD, n = 8–10mice/group. (B) Six days after s.c. injection of TC1 cells, mice were injected
with Ad.E7 (109 pfu) and 2 days later pumps deliveringUsp7i (1mg/kg/day)were inserted; panel (mean± SEM) shows serialmonitoring of tumor volumes inmice (10/group) that were
either untreated, or received Ad.E7 or Usp7i alone, or their combination. Panels C-E show effects of therapy, at 13 days post-Ad.E7 vaccination, including: (C) %tetramer + CD8 tumor
inﬁltrating lymphocytes (TILs) (**p b 0.01 vs. untreated or Usp7i-treated groups); (D) % IFNγ+ CD8 cells among all CD8 TILs (**p b 0.01 vs. other groups); and (E) % Foxp3+ CD4 T
cells among all CD4 TILs (**p b 0.01 vs. other groups). (F) Combination therapy with anti-PD-1 mAb (5 mg/kg/4 days) and Usp7i (1 mg/kg/day) in mice bearing TC1 lung tumors; day
0 on the x-axis indicates when implanted tumor volumes had reached ~150 mm3 and therapy was begun; mean ± SD, 8 mice/group, **p b 0.01 vs. other groups.
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proteases andmetalloproteases (Reyes-Turcu et al., 2009). The cysteine
proteases include ubiquitin C-terminal hydrolases, ubiquitin speciﬁc
protease, ovarian tumor proteases, and Machado-Joseph domain
proteases, whereas the sole metalloprotease group comprises several
Jab1/Mpn/Mov34 domain proteases. DUBs typically have a catalytic do-
main and several accessory domains that facilitate target interaction,
protein-protein interactions, cell localization and other actions. Of the
N50 mammalian USPs (Reyes-Turcu et al., 2009), some 21 USPs were
detected in human Tregs and identiﬁed by ChIP studies as possible
targets of FOXP3 (Sadlon et al., 2010). We focused on Usp7 for several
reasons, including a report of Usp7 regulating Foxp3 expression in
murine Treg cells (van Loosdregt et al., 2013). However, that study
used a DUBi small molecule, that unlike compounds P5091 or 564, has
several hundred fold greater potency against Usp8 vs. Usp7 (Colombo
et al., 2010). Critically, Usp8 is well-expressed in Foxp3+ Treg cells(http://www.ncbi.nlm.nih.gov/geoproﬁles/?term=usp8+AND+Foxp3),
and can stabilize expression of Ndrp1/RNF41 that is important to cytokine
receptor (e.g. IL-2R) and retinoic acid receptor signaling (3–5), and vital
for Foxp3 stabilization in thymic and/or induced Tregs (De Ceuninck et
al., 2013; Jing et al., 2008; Wu et al., 2004).
In contrast, the current study used highly speciﬁc Usp7i small mole-
cules, as well as conditional gene deletion, to deﬁnitively evaluate the
effects of Usp7 targeting on host immune responses, including in the
context of immuno-oncology. Our work does indicate a role for Usp7
in regulating Foxp3, but also identiﬁes a potentially even more impor-
tant action in regulating Tip60 in Treg cells. Usp7 can deubiquitinate
and stabilize expression of Tip60 in transfected 293T cells (Dar et al.,
2013) and in cultured 3T3-L1 adipocytes (Gao et al., 2013), indicating
the potential for Usp7 to regulate the actions of Tip60 in non-hemopoi-
etic cells. However, the current study highlights the role of Usp7 in reg-
ulation of Tip60 in Treg cells, as illustrated in schematic form in Fig. 7.
Fig. 7. Schematic of proposed interaction of Usp7i with Foxp3+ Treg cells. Lysine residues in both Foxp3 and Tip60 in Treg cells are subject to polyubiquitination, leading to protein
turnover via their proteasomal degradation. Through the actions of Usp7, deubiquitinated lysine residues can be acetylated, leading to protein stabilization. While multiple HATs can
acetylate Foxp3, Tip60, which can auto-acetylate, is unique in mediating acetylation of 2 lysine residues required for Foxp3 dimerization. Dimerized Foxp3 can then bind to DNA and
mediate effects on gene transcription in Treg cells (e.g. upregulation of genes encoding Ctla4 and IL-10 and inhibition of genes encoding IL-2 and IFN-γ).
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anticipated to promote the ubiquitination and proteasomal degradation
of many cell proteins. However, the exquisite speciﬁcity of Foxp3 for
Treg cells, and the key role of Tip60 in promoting Foxp3 dimerization,
provides a mechanism by which Usp7i compounds can have dominant
effects on Foxp3+Tregs over that of other immune cell types, including
host Teff cells. Likewise, within Treg cells, the requirement of Tip60-me-
diated acetylation for Foxp3 dimerization and Treg function makes this
Usp7-regulated pathway a critical target for pharmacologic modulation
of Treg cells using Usp7i compounds.
Usp7 is thought to exist in equilibrium between inactive and active
forms, and its activity is enhanced allosterically by themetabolic enzyme,
GMPS, which binds and activates the HUBL domain of Usp7, increasing
the ubiquitin binding and catalytic activity of Usp7 by 100-fold (Faesen
et al., 2011). Although details of the regulation of Usp7 activity in Tregs
are still incomplete, our Usp7i data indicate that the catalytic site is
important for the functions of Usp7 in Treg cells. Whether an additional
scaffolding or adaptor function of Usp7 can play an important role inTreg cells, e.g. by contributing to the assembly of large molecular com-
plexes, remains to be determined.
The effects of Usp7 targeting on Foxp3+ Treg biology in our studies
were profound and multifaceted. While both Foxp3 transcription and
translation appeared unimpaired under basal conditions, Foxp3-depen-
dent Treg functions were disrupted. An example of this dysfunction
involved Treg production of IL-2. A deﬁning characteristic of normal
Foxp3+ Treg cells is their dependence upon IL-2 production by adja-
cent T cells for their survival (Fontenot et al., 2005; Gavin et al., 2007).
This is due to Foxp3 binding to the IL-2 promoter in Tregs and inhibiting
IL-2 expression. Our ChIP studies conﬁrmed decreased binding of Foxp3
to the IL-2 promoter of Usp7-targeted Tregs, along with their produc-
tion of IL-2 and other normally repressed cytokines. This failure to
suppress IL-2, despite production of Foxp3 mRNA and protein, became
explicable once the inhibitory effects of Usp7 targeting on Foxp3 dimer-
ization and oligomerization were detected. Likewise, the more rapid
and greater effects of Usp7 targeting on Tip60 vs. Foxp3 ubiquitination
and turnover are consistent with a key role for regulation of Tip60
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Treg cells, Foxp3 dimerization and DNA binding is impaired and Treg
function abrogated, despite ongoing Foxp3 mRNA and protein produc-
tion. These effects of Usp7 on post-translational pathways in Tregs pro-
vide an important new insight of potential signiﬁcance in anti-cancer
therapy.
The ability of Usp7 targeting to selectively diminish Treg function
has practical signiﬁcance in cancer therapy, given the availability of
highly speciﬁc and potent Usp7i compounds. Though initially identiﬁed
as a protein associated with herpes simplex virus, Usp7 became widely
known as its role in regulation of the p53 pathway was characterized
(36, 37). Usp7 deubiquitinatesMdm2 and enhances its E3 ligase activity
towards p53 protein, though p53-independent actions are recognized
(Nicholson and Suresh Kumar, 2011). Hence, inhibition of Usp7 is
thought to inactivate Mdm2 and thereby activate p53, resulting in inhi-
bition of cell cycle progression and tumor cell apoptosis. In the current
studies, the negligible direct effects of Usp7i administration on tumor
growth in vivo are consistent with the low levels of p53 and Mdm2 in
the tumors employed in our studies, and contrast with a previous
study in which compound P5091 had direct effects on the growth of
human multiple myeloma cells as xenografts in immunodeﬁcient mice
(Chauhan et al., 2012). Levels of p53 and Hdm2, the human counterpart
of Mdm2, were considerably higher in those myeloma cells than in TC1
or AE.17 cells (Fig. S19). Levels of p53 were also low in murine Tregs,
with or without Usp7 deletion, such that the effects of Usp7i on tumor
growth in immunocompetent hosts likely reﬂect disruption of Treg
function, via effects on Tip60 and Foxp3, than via a p53-dominant
mechanism. The increased resistance of Usp7i-treated Teff cells to
Treg suppression is an additional therapeutic mechanism resistance of
Usp7i-treated Teff cells to suppression by untreated WT Tregs
(p b 0.05) (Fig. 4B, Fig. S15), albeit as yet unexplored. However, it is to
be expected that in some tumor models in syngeneic hosts, the effects
of Usp7i administration will include direct anti-tumor effects as well
as immune actions, and the relative contributions of these mechanisms
may differ. In either situation, increased anti-tumor activity would be
expected.
The current data also show that Usp7i therapy, likely via its inhibito-
ry effects on Tregs, can potentiate the effects of antitumor vaccination,
PD-1 targeting, and other immunotherapies in experimental models.
This may increase the efﬁcacy of a given approach, allow reduced inten-
sity of therapy with a single agent, and reduce development of resis-
tance as a result of multiple mechanisms of action. Hence, the further
development and clinical testing of Usp7i compounds appears a logical
and potentially valuable new approach in the immunotherapy of
cancer.
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